Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Abstract

Background: Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods: Virus neutralizing antibody titres, as a rapidly available but highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of the second dose of the vaccine. Findings: Sex and time since the second dose had little association with the antibody titres. Age, however, was highly relevant: measurable antibody levels were present in about 90% of individuals below the age of 50, but antibody production after BBIBP-CorV vaccination was strongly reduced with increasing age. A large number of elderly subjects, reaching 25% at 60 years, and up to 50% at ages over 80, were found not to produce any protective antibody. Interpretation: Neutralizing antibody titre, as a correlate of protection for COVID-19 disease susceptibility, should help to evaluate the effectiveness of the BBIBP-CorV vaccine. Results suggest that proper measures should be undertaken to prevent a potential outbreak of COVID-19 in BBIBP-CorV vaccinated but eventually unprotected elderly individuals. Funding: No specific funding was used to carry out the study.

Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with age and gender among health care workers

“…Similar to our study, gender was slightly correlation with the antibody titers, but antibody titers were highly correlated with age. Measurable antibody levels were detect in approximately 90% of subjects under 50 years of age, but production of the antibody was decreased sharply with age [43]. Nevertheless, in our study, age had no signi cant effect on the e cacy of the Sinopharm vaccine.…”

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

“…Hence, future investigations must include serial titer levels over a broad timeframe in order to have a better understanding of the changes in antibody titers over time. To the best of our knowledge, this is the first study to compare the antibody levels between an mRNA vaccine and an inactivated virus vaccine in the Middle East and North Africa (MENA) region and is among the first studies to compare these vaccines worldwide [17].…”

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models

“…For the evaluation of neutralizing antibodies, the ability of antibodies to block SARS-CoV2 infection is examined ( 60 ). Different vaccines such as BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine ( 61 ), Rabies virus-based COVID-19 vaccine CORAVAX™ ( 62 ), and Sputnik V vaccine ( 63 ) also led to the production of significant amounts of neutralizing antibodies which appeared to correlate with an elevated protection and decreased susceptibility to the COVID-19 disease. Comparison of neutralizing antibodies elicited by SARS-CoV-2 adenoviral vector and mRNA vaccine exhibited that Ad26.COV2.S-expressed antibodies revealed low neutralizing capacity in a significant portion of vaccinated individuals whereas mRNA-1273 and BNT162b2-elicited antibodies displayed a modest neutralization against different variants of SARS-CoV-2 including Lambda, Delta, Delta plus, and Beta ( 64 ).…”